NCT05883709

A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL

A Real-world Study Evaluating the Safety and Efficacy of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 15 (estimated)
• Sponsor: Zhao Weili · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

To evaluate the real-world efficacy of Tafasitamab combined with Lenalidomide base regimen in patients with relapsed or refractory DLBCL, with objective response rate as the primary end point.

Detailed description

This study retrospectively collected the data of patients previously treated with Tafa and divided them into two coords according to different protocols received. Cohort 1 was Tafa combined treatment group, which could include Tafa combined with lenalidomide, Tafa combined with Lenalidomide plus BTK inhibitor, Tafa combined with Lenalidomide plus chemotherapy (including ADC). Cohort 2 was treated with sequential CAR T or graft after Tafa combination therapy.

Conditions

• Diffuse Large B-cell Lymphoma

Interventions

Type	Name	Description
DRUG	Tafasitamab Injection	The combination of Tafasitamab and lenalidomide based treatment was selected according to the specific conditions of patients

Timeline

• Start date: 2023-07-01
• Primary completion: 2023-12-30
• Completion: 2024-12-30
• First posted: 2023-06-01
• Last updated: 2023-06-01

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study